Immune cell boost: new hope for kids with tough neuroblastoma?

NCT ID NCT06450041

Recruiting now Disease control Sponsor: New Approaches to Neuroblastoma Therapy Consortium Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This phase 2 trial tests a new approach for children and young adults with relapsed or hard-to-treat neuroblastoma. Patients receive donor immune cells (NK cells) along with standard chemotherapy and an antibody therapy. The goal is to see if this combination can shrink tumors or stop the cancer from growing. The study will enroll 62 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: donor natural killer (NK) cells, temozolomide, irinotecan, dinutuximab, and sargramostim
What this could lead to: If successful, this combination could offer a new treatment option for children with neuroblastoma that has come back or not responded to standard therapy.
What could go wrong: This is a phase 2 trial with only 62 participants, so results are preliminary. The treatment involves strong chemotherapy and immune cells, which can cause serious side effects like low blood counts and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROBLASTOMA

Contacts and locations

Locations

Boston Children's Hospital, Dana-Farber Cancer Institute.
NOT_YET_RECRUITING

Boston, Massachusetts, 02115, United States
C.S Mott Children's Hospital
NOT_YET_RECRUITING

Ann Arbor, Michigan, 48109, United States
Children's Hospital Colorado
RECRUITING

Aurora, Colorado, 80045, United States
Children's Hospital Los Angeles
RECRUITING

Los Angeles, California, 90027-0700, United States
Children's Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104-4318, United States
Cincinnati Children's Hospital Medical Center
NOT_YET_RECRUITING

Cincinnati, Ohio, 45229-3039, United States
Comer Children's Hospital, University of Chicago
NOT_YET_RECRUITING

Chicago, Illinois, 60614, United States
Cook Children's Medical Center
RECRUITING

Fort Worth, Texas, 76104, United States
Nationwide Children's Hospital
RECRUITING

Columbus, Ohio, 43205, United States
Seattle Children's Hospital
NOT_YET_RECRUITING

Seattle, Washington, 98105, United States
St. Jude Children's Research Hospital
RECRUITING

Memphis, Tennessee, 38105, United States
UCSF Benioff Children's Hospital
RECRUITING

San Francisco, California, 94143, United States
University of Texas Southwestern
RECRUITING

Dallas, Texas, 75235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.